Metastases Directed Therapy for Oligometastatic Breast Cancer

Summary

This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not

Eligibility

Inclusion Criteria:

* Female patients aged 18 to 70 years.
* Pathological evidence of breast cancer, any grade, any T stage.
* Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions.
* Performance status ≤ 2
* No pre-existing conditions that may prohibit radiotherapy.

Exclusion Criteria:

•.Pregnant and lactating women.

* Prior radiotherapy to affected site(s) in less than a year.
* Active Connective tissue diseases (e.g Rheumatoid Arthritis).
* Progression to widespread metastatic disease
* Cases with brain metastasis

Conditions4

Browse More Trials